INTRODUCTION
Since Pauson et al. [1, 2] discovered this metalorganic compound ferrocene in 1951, its derivatives have been extensively researched. The ferrocene derivatives exhibit good fat solubility through the cell membrane and combine with intracellular enzymes. [3] Since the 1980s, Kopf-Maier et al. [4, 5, 6 ]discovered that ferrocene derivatives have a inhibitory effect on malignant tumor cells proliferation. From 1980, the antitumor activity has been discovered in metalorganic compounds, including alkyl ferrocene, ferrocene alkyl azole, yokes of ferrocene biological macromolecule compounds, and ferrocene-modified cisplatin. [7] The human breast cancer is a major public health problem. Seventy-five percent of breast cancers in postmenopausal women are estrogen-dependent [8] . Meanwhile, estrogens are principally produced by ovaries in premenopausal women and continue to be synthesized by non-ovarian tissues [9] , such as the breast tissue in postmenopausal women [10] . Estrogens are biosynthesized from circulating androgens through an aromatization reaction of the steroidal A-ring, catalyzed by the enzyme aromatase (AR, CYP19). The inhibition of estrogen biosynthesis by the third-generation aromatase inhibitors exemestane, letrozole, and anastrozole is the frontline therapy for postmenopausal estrogen-dependent breast cancer [11, 12] . The enzyme has been the subject of intensely biochemical and biophysical investigations for the past 40 years [13] .
In the current work, we used a newly refined aromatase-androstenedione complex structure ( Figure 1 ; PDB code 3EQM [14] ), which had overall quality and refinement parameter statistics for molecular docking to find a new aromatase inhibitor. We synthesized a series of ferrocene heterocyclic derivatives and evaluated the new compounds for their antitumor activities against human breast cancer MCF-7 cells in vitro. The objective was to explore the influence of ferrocene heterocyclic derivatives, which were modified by seven heterocycles (1b-7b) on tumor cell activity to identify better candidate compounds against the human breast cancer. Surflex-Dock was used to explain the probable reasons why the compounds have antitumor activities, wherein the small molecule ligands which were positioned in the active site of the target receptor where the original ligand ASD (4-ANDROSTENE-3-17-DIONE) was extracted. Then, the designed compounds were led into the cavity.
EXPERIMENTAL SECTION

Materials and methods
The melting points were recorded on a WPS-2A digital melting point apparatus and they were uncorrected. 1 H NMR and 13 C NMR spectra were recorded at 500 MHz on a Bruker Avance III 500 spectrometer with TMS as the internal standard. IR spectra were recorded on a Nicolet 6700 spectrometer (KBr). The mass spectra were recorded on a Shimadzu 2020 spectrometer. The HR-MS spectra were recorded on a SolariX-70FT-MS Bruker spectrometer. All reagents were analytical grades. /L). In the eight heterocyclic ferrocene derivatives, results indicated that they had a pyridine group and produced ester which is more effective in inhibiting MCF-7 cells than that of amide-producing heterocyclic ferrocene derivatives without a pyridine group. Docking simulation was also performed to position compounds into the human enzyme aromatase (AR, CYP19) active site adequately to explain the probable reasons why the compounds have antitumor activities. The authors observed that compound Fc17, which had the highest affinity to the receptor, was stabilized by two respective hydrogen bonds with Thr310 and Ser314.
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Synthesis of 2a-4a
The synthesis of ferrocenylacetic acid (2a) was based on references [15] and [16] , whereas the syntheses of ferrocene acyl propionic acid (3a) and ferrocene acyl butyric acid (4a) were based on reference [17] .
Synthesis of compounds Fc5, Fc6, Fc12 and Fc17
Ferrocene carboxylic acid (1.0 mmol), EDCl (206.0 mg, 1.0 mmol), and DMAP (12.2 mg, 0.1 mmol) were dissolved in dichloromethane (30.0 ml) and then stirred for 45 min in ice water. Then, 5b or 6b (2.0 mmol or 4.0 mmol) was added to the solution, and the mixture was stirred for 24 h. After reaction completion as monitored by thin-layer chromatography, the solution was washed with brine and extracted with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain the crude product. The residue was purified by flash chromatography (silica gel and ethyl acetate/petroleum ether) to provide the target compounds. Ferrocene carboxylic acid (2 mmol), EDCl (412 mg, 2 mmol), and HOBt (270 mg, 2 mmol) were dissolved in dichloromethane (30 ml) and then stirred for 45 min in ice water. Then, 1b-4b or 7b (2.0 mmol or 4.0 mmol) was added to the solution and the mixture was stirred for 24 h. After the reaction completion, as monitored by thin-layer chromatography, the solution was washed with brine and extracted with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain the crude product. The residue was purified by flash chromatography (silica gel and ethyl acetate/petroleum ether) to provide the target compounds.
1-Ferrocene formyl benzotriazole (Fc1)
Mp.145.6-147. 
Antiproliferative assays
The antitumor activities of the target compounds on
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05001-p. 3 MCF-7 cells in vitro were tested by MTT assay. The cells were collected in the log phase. The concentration of the cell suspension was adjusted, and the cell suspension (100 μL) was transferred to each well of a 96-well flat-bottom plate. The density of tested cells was adjusted to 1000-10 000 cells per well by decking (the wells on the edge were filled with sterile PBS). The cells were cultured at 37 °C for 24 h in a 5% CO 2 incubator until a monolayer covered the bottom of the well. Subsequently, the cells were exposed to a concentration gradient of the different drugs, with 6 grads and 100 µL per well. The cells were then cultured for 24 h in a 5% CO 2 incubator at 37 °C and observed with an inverted microscope. Subsequently, the supernatant was discarded and 20 μL of MTT solution (5 mg/mL, that is, 0.5% MTT) was added to each well.
The cells were cultured for another 4 h. Thereafter, the supernatant was discarded, 150 μL DMSO was added to each well, and the cells were agitated for 10 min on a low-speed shaker until the crystals were fully dissolved. Finally, an automated multi-microplate reader was used to measure the absorbance of each well at 570 and 630 nm.
Docking simulations
All docking calculations were carried out using Surflex-Dock (SYBYL-X2.0) in the docking mode of surflex-dock (SFXC). The X-ray structure of the AR crystal structure (PDB code 3EQM) was selected as the template for the modeling study and downloaded from the RCSB Protein Data Bank (http://www.rcsb.org/pdb/explore/explore.do?structure Id=3EQM). For ligand preparation, the ligand structure was generated and added with Gasteiger-Huckel charges, and the force field was tripos. At the same time, the energy minimization was needed for the process of dealing with ligand, so the maximum iterations were performed 1000 times and the gradient was set to 0.05 kcal/(mol·A).For the protein preparation, the ligand ASD was extracted from the crystal structure. Then, all water existing in the protein, as well as in the ligand HEM and PO4, were removed. The selected structure was subsequently analyzed. The sidechain was repaired, the hydrogen atoms were added, and the type atoms were fixed. Then, terminus treatment was performed, the sidechain amides were added, and sidechain bumps were fixed. The final step was staged minimization, and then a pocket was produced as our active site.
RESULTS AND DISCUSSION
Chemistry
The synthesis route of ferrocene heterocyclic derivatives (Fc1 to Fc18) is outlined in Scheme 1 [15] . As it is reported, the synthesis of compounds (Fc1-Fc18) was synthesized with the ferrocenyl carboxylic acid and different heterocycles with the help of EDCl, HOBt, or DMAP in anhydrous methylene dichloride. All synthesized compounds Fc1-Fc18 (Figure 3) provided satisfactory elementary analytical and spectroscopic data. NMR, HR-MS, ESI-MS, and IR spectra were consistent with the assigned structures.
Bioassay
To test the anticancer activities of the synthesized compounds, we evaluated the representative compounds Fc1, Fc3, Fc9-Fc12, Fc14, and Fc17 in MCF-7 cells as summarized in Table 1 . We observed that Fc3, Fc11, Fc12, and Fc17 displayed better inhibitory effect against MCF-7 cells than other four compounds. Their IC50 values were respectively 39.2, 44.2, 48.3, and 24.2 (μmol/L).
Based on the molecular structures, eight heterocyclic ferrocene derivatives that had a pyridine group and owned ester were more effective in inhibiting MCF-7 cells than that of ferrocene heterocyclic derivatives without a pyridine group and did not own amide. Eight heterocyclic ferrocene derivatives substituted with a pyridine group had better biological activity against MCF-7 cells than the compounds that lacked a pyridine group. Thus, introducing a pyridine group into ferrocene better improved the antitumor activity against MCF-7 cells of Fc11, Fc12, and Fc17. In addition, from the perspective of docking simulation, we try to find out the probable reasons why the compounds have antitumor activities.
Molecular docking
To clarify the binding mode of heterocyclic ferrocene derivatives with aromatase compared with exemestane (Aromasin; one of the three aromatase inhibitors approved by the US Food and Drug Administration), the 18 compounds Fc1-Fc18 molecules were docked into the active site of aromatase where the original ligand was removed. The crystal structure of the enzyme was obtained from the Protein Data Bank (PDB code 3EQM). According to the previous literature 14 (Figure 3) , the residues comprising the catalytic cleft are Ile 305, Ala 306, Asp 309 and Thr 310, Trp 224, Ile 133, Phe 134, Val 370, Leu 372, Val 373, Met 374, and Leu 477. The 2D interaction maps between the compounds and the 3EQM protein crystal structure are displayed in Figures 5A-5D , which can aid in elucidating the interaction forces. Examination of the crystal structure showed the existence of only one hydrogen bond consisting of residues Met374 and the N atom, which is involved in the binding between the compound and the active site ( Figure 5A ). The number of van der Waals displayed in Fc11 (Figure 5B) exceeded that in Fc3, while the Met374 residues just played a role as van der Waals forces. Unfortunately, only one
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Unfortunately, only one pink electrostatic interaction existed between Fc11 and Leu477. The binding mode of Fc12 interaction with the enzyme protein is presented in Figure 5C . Docking results revealed that one hydrogen bond between the N atom from Fc12 with the Ser314 residues. Meanwhile, Pro429, Cys437, and Phe430 that located in the binding pocket of the protein played an electrostatic role in the interaction of Fc12, as well as in the interaction of Met374, Met364, Leu477, and so on. They are with Fc12 by van der Waals forces.
At last, Fc17 had two hydrogen bonds involving the O and N atoms from the compound and the residues Thr310 and Ser314 respectively (Figure 5D) . Except for the two hydrogen bonds, the electrostatic interaction between Fc12 and Cys437 can be also clearly seen in Fc17 around the active site. According to the 2D interaction maps, Fc17 may be surrounded by 20 residues such as Met447 and Leu477. Therefore, we anticipated that Fc17 could embed well into the active pocket and may have considerably better physicochemical properties than other ferrocene heterocyclic derivatives. Furthermore, the enzyme surface model ( Figure 5 ) revealed that Fc17 occupied the active pocket and was bound to an active conformation of AR. Therefore, we inferred the probable reason for the Fc17 had better antitumor activities than other compounds in the eight representative compounds.
05001-p. 7 A series of ferrocene heterocyclic derivatives (Fc1-Fc18) was synthesized, and eight of them were evaluated for their antitumor activities and found to exhibit antitumor activity against MCF-7 cells. Among the eight compounds, Fc3, Fc11, Fc12, and Fc17 demonstrated more anticancer activities against MCF-7 cells [IC 50 values are respectively 39.2, 44.2, 48.3, and 24.2 (μmol/L),]. Docking simulation studies were performed to position Fc17 in the human aromatase active site to explain the probable reasons why the compounds have antitumor activities. Analysis of the binding conformation of Fc17 in the active site of the enzyme demonstrated that Fc17 had two hydrogen bonds which are composed of O and N atoms from the compound and residues Thr310 and Ser314. The results of our study can contribute to the design and synthesis of a leading compound, Fc17, for the development of new therapeutic agents against human breast cancer. 
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05001-p.8 Figure 6 . Docking result of the compounds in the study. The binding site (3EQM) surrounding the compound Fc17, the view of the pocket and the surfaces was transparent and presented by electrostatic potential, the secondary structure of the protein is displayed by an opaque ribbon. Hydrogen bonds are shown as yellow dashed lines. The inhibitor is also shown as a gray stick model.
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